Metformin Pharmacogenomics: Current Status and Future Directions
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin remains the most widely used first-line pharmacotherapy for its treatment; however, marked interindividual variability in response and few clinical or biomarker predictors of response reduce its optimal use. As clinical care moves toward precision medicine, a variety of broad discovery-based “omics” approaches will be required. Technical innovation, decreasing sequencing cost, and routine sample storage and processing has made pharmacogenomics the most widely applied discovery-based approach to date. This opens up the opportunity to understand the genetics underlying the interindividual variation in metformin responses in order for clinicians to prescribe specific treatments to given individuals for better efficacy and safety: metformin for those predicted to respond and alternative therapies for those predicted to be nonresponders or who are at increased risk for adverse side effects. Furthermore, understanding of the genetic determinants of metformin response may lead to the identification of novel targets and development of more effective agents for diabetes treatment. The goals of this workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases were to review the state of research on metformin pharmacogenomics, discuss the scientific and clinical hurdles to furthering our knowledge of the variability in patient responses to metformin, and consider how to effectively use this increased understanding to improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“Recent studies in conditional Ampk knockout mice challenge the notion that AMPK activation is required for the effects of metformin on glycemia (17), although genetic variants in AMPK subunits in humans have now been associated with metformin clinical responses at the nominal significance level (18).”
BackgroundThe Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Metformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
Self-citationThe Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
The Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.5.1566 · Cited by 333
Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., et al. (2010) · Diabetes · doi:10.2337/db10-0543 · Cited by 271
Self-citationThe U.K. Prospective Diabetes Study. A review
Turner, R. C. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.c35 · Cited by 267 · cited 3×
“The first and best known large trial demonstrating the efficacy of metformin is the UK Prospective Diabetes Study (UKPDS) (14).”
BackgroundInfluentialThe Diabetes Prevention Program Research Group [Prepared by Jill Crandall, D. S. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.10.1075 · Cited by 254 · cited 1×
“Variability in the ability of metformin to prevent diabetes was seen, with it being less effective in the older participants (35) but more effective in the more obese participants (36).”
Background
Cited by
Gureev, A. P., Shaforostova, E. A., & Popov, V. N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00435 · Cited by 643
Hu, C., & Jia, W. (2018) · Diabetes · doi:10.2337/dbi17-0013 · Cited by 386
Metformin: A Hopeful Promise in Aging Research
Novelle, M. G., Ali, A., Diéguez, C., Bernier, M., & de Cabo, R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025932 · Cited by 178
Inhibition of AMP kinase by the protein phosphatase 2a heterotrimer, PP2APpp2r2d
Joseph, B. K., Liu, H.-Y., Francisco, J., Pandya, D., Donigan, M., Gallo-Ebert, C., Giordano, C., Bata, A., & Nickels, J. T. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626259 · Cited by 91
“Metformin, one of the most used drugs to treat diabetes, targets and activates AMP kinase (35).”
BackgroundCheki, M., Shirazi, A., Mahmoudzadeh, A., Bazzaz, J. T., & Hosseinimehr, S. J. (2016) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2016.09.001 · Cited by 72
Metadata
- Authors
- Pawlyk, A. C., Giacomini, K. M., McKeon, C., Shuldiner, A. R., & Florez, J. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-07-17
- Volume
- 63
- Issue
- 8
- Pages
- 2590-2599
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2153996274
- Cited by
- 136
- References
- 16
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.